1α,25(OH)2D3 attenuates IL-6 and IL-1β-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-κB signaling pathways
- 95 Downloads
Metabolic syndrome is characterized by macrophage infiltration and inflammatory responses—metaflammation in adipose tissue. IL-6 and IL-1β could mediate the inflammatory responses in macrophage stimulated-preadipocytes by modulating MAPK and NF-κB pathways. To test this hypothesis we used antibodies to block IL-6 and IL-1β action in macrophage conditioned medium (MacCM)-stimulated human white preadipocytes. Moreover, as interventions that prevent this could potentially be used to treat or prevent metabolic syndrome, and 1α,25(OH)2D3 has previously been reported to exert an anti-inflammatory action on macrophage-stimulated adipocytes, in this study we also investigated whether 1α,25(OH)2D3 could attenuate inflammatory responses in MacCM-stimulated preadipocytes, and explored the potential anti-inflammatory mechanisms.
Human white preadipocytes were cultured with 25% MacCM for 24 h to elicit inflammatory responses. This was confirmed by measuring the concentrations and mRNA levels of major pro-inflammatory factors [IL-1β, IL-6, IL-8, monocyte chemoattractant protein (MCP)-1 and regulated on activation, normal T cell expressed and secreted (RANTES)] by ELISA and qPCR, respectively. IL-6 and IL-1β actions were blocked using IL-6 antibody (300 ng/ml) and IL-1β antibody (15 μg/ml), respectively. Potential anti-inflammatory effects of 1α,25(OH)2D3 were investigated by pre-treatment and treatment of 1α,25(OH)2D3 (0.01 to 10 nM) for 48 h in MacCM-stimulated preadipocytes. In parallel, western blotting was used to determine inflammatory signaling molecules including relA of the NF-κB pathway and p44/42 MAPK modified during these processes.
MacCM enhanced the secretion and gene expression of IL-1β, IL-6, IL-8, MCP-1 and RANTES by increasing the phosphorylation levels of relA and p44/42 MAPK in preadipocytes, whereas blocking IL-6 and IL-1β action inhibited the inflammatory responses by decreasing p44/42 MAPK and relA phosphorylation, respectively. Furthermore, 10 nM of 1α,25(OH)2D3 generally inhibited the IL-6 and IL-1β-mediated inflammatory responses, and reduced both p44/42 MAPK and relA phosphorylation in MacCM-stimulated preadipocytes.
1α,25(OH)2D3 attenuates IL-6 and IL-1β-mediated inflammatory responses, probably by inhibiting p44/42 MAPK and relA phosphorylation in MacCM-stimulated human white preadipocytes.
KeywordsHuman white preadipocytes Macrophages IL-6 IL-1β Inflammatory responses relA p44/42 MAPK 1α,25(OH)2D3
mitogen-activated protein kinase
macrophage conditioned medium
monocyte chemoattractant protein-1
regulated on activation, normal T cell expressed and secreted
Metabolic syndrome is a clustering of clinical findings consisting of abdominal obesity, high glucose, high triglycerides, low high-density lipoprotein cholesterol levels, and hypertension . Metaflammation in adipose tissue, characterized by infiltration of macrophages, local gene expression and secretion of pro-inflammatory factors, especially IL-6 and IL-1β , is considered a potential factor contributing to development of the metabolic syndrome . Moreover, it is notable that inflammatory signaling molecules including relA (NF-κB p65) and MAPK family members [i.e. p44/42 (ERK1/2)] activated in adipose tissue during metabolic syndrome, could trigger metaflammation and insulin resistance [3, 4]. It is therefore important to determine whether IL-6 or IL-1β mediates adipose tissue metaflammation during macrophage infiltration via modulating MAPK or NF-κB pathway, to help further elucidate the pathophysiology of metabolic syndrome.
Attenuating adipose tissue metaflammation promotes insulin sensitivity , and might be a potential strategy to treat or prevent metabolic syndrome. Accumulated evidence suggests that macrophages play a key role in influencing the proliferation, survival and differentiation of preadipocytes [6, 7, 8, 9, 10], which are essential in maintaining adipose tissue homeostasis . Most importantly they might even induce or aggravate metaflammation by stimulating preadipocytes to express and secrete a variety of cytokines, most of which are pro-inflammatory [12, 13, 14]. In vitro studies have shown that 1α,25(OH)2D3 exerts anti-inflammatory actions on lipopolysaccharide (LPS) and macrophage-stimulated adipocytes, by reducing the release and gene expression of major pro-inflammatory factors including IL-6, IL-8 and MCP-1 [15, 16]. However, the anti-inflammatory effects of 1α,25(OH)2D3 on macrophage-stimulated preadipocytes, remains to be explored in detail.
In this study, we aimed firstly to test whether IL-6 or IL-1β is critical in mediating inflammatory responses in MacCM-stimulated preadipocytes, in terms of pro-inflammatory gene expression and secretion; and secondly to determine the inflammatory signaling pathways activated by examining the phosphorylation of signaling molecules including relA of the NF-κB pathway and p44/42 MAPK. Finally, we investigated whether 1α,25(OH)2D3, could attenuate the inflammatory responses in MacCM-stimulated preadipocytes, and explored the potential anti-inflammatory mechanisms.
Preparation of MacCM
The human THP-1 monocytic cell line was kindly provided by Professor Helen R Griffiths (Aston University, UK). Monocytes were cultured in T75 flasks in RPMI-1640 medium (Sigma-Aldrich, UK) supplemented with 10% fetal bovine serum and 100 U/ml penicillin, 100 μg/ml streptomycin, and incubated at 37 °C in 95% air and 5% CO2. When the monocyte density reached 1 × 106 cells/ml, the differentiation to pro-inflammatory M1 dominant macrophages was induced by 100 nM phorbol 12-myristate 13-acetate (Sigma-Aldrich, UK) for 48 h, and then activated by 1 μg/ml LPS  and 1 mM ATP (Sigma-Aldrich, UK) for a further 24 h in RPMI-1640 before medium collection. The MacCM was filtered through 0.22 μm filters and stored at − 80 °C.
Culture of human white preadipocytes
Human white preadipocytes derived from subcutaneous adipose tissue of a female Caucasian subject (BMI 21; age 44 years) were obtained from PromoCell (Germany). The preadipocytes were cultured in T25 flasks then sub-cultured into 12-well plates (seeding density: 5000 cells per cm2) in preadipocyte growth medium (PromoCell, Germany) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B, and incubated at 37 °C in 95% air and 5% CO2.
MacCM stimulation and blockade of IL-6 and IL-1β action
When confluence was reached, preadipocytes (n = 6 wells per group) were cultured for 24 h in preadipocyte growth medium, which was replaced with 25% MacCM (diluted in RPMI-1640) to elicit inflammatory responses, together with IL-6 antibody (300, 350 and 450 ng/ml) or IL-1β antibody (15 μg/ml as previously established ) (R&D Systems, UK) to block IL-6 or IL-1β action by neutralization for a further 24 h before cell and supernatant collection. Isotype control mouse IgG at the same concentrations confirmed that non-specific binding did not block inflammatory responses (data not shown). The control received a mock treatment of 25% preadipocyte growth medium (diluted in RPMI-1640).
MacCM stimulation and 1α,25(OH)2D3 pre-treatment and treatment
When confluence was reached, preadipocytes (n = 6 wells per group) were pre-treated with 1α,25(OH)2D3 (ENZO Life Sciences, USA) (reconstituted in DMSO to a concentration of 1 μg/μl and diluted to final concentrations of 0.01–10 nM in preadipocyte growth medium). The pre-treatment was to boost the potential anti-inflammatory effects of 1α,25(OH)2D3 as established previously . After 24 h the pre-treatment media were discarded. Then, 25% MacCM (diluted in RPMI-1640) was added together with 1α,25(OH)2D3 (0.01–10 nM) for a further 24 h before cell and supernatant collection.
Measurement of inflammatory responses
Cytokine release of the pooled cell supernatants (n = 6) were screened by Human Cytokine Array Panel A following the manufacturer’s instructions (R&D Systems, UK) and Molecular Imager ChemiDoc XRS+ System (Bio-Rad, UK). The results were presented as pixel density relative to the references of the arrays. The secretion levels of major pro-inflammatory factors including IL-1β, IL-6, IL-8, MCP-1 and RANTES were measured in duplicate using human ELISA kits following the manufacturer’s instructions (R&D Systems, UK) and SPECTROstar Nano Microplate Reader (BMG LABTECH, Germany). The results were also normalized to total cell protein content (measured by Thermo Scientific Pierce BCA Protein Assay Kit, UK) and presented as μg(cytokine)/mg(cell protein). The mRNA levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES in preadipocytes were measured in duplicate using TaqMan gene expression assays (Applied Biosystems, UK), qPCR core kit (Eurogentec, Belgium) and Stratagene Mx3005P instrument system. The results were normalized to the values of reference gene PPIA  and presented as fold changes of Ct value relative to controls using the 2−ΔΔct formula . The intracellular levels (densities) of inflammatory signaling molecules including relA, phosphorylated relA, p44/42 MAPK, phosphorylated p44/42 MAPK, p38 MAPK and phosphorylated p38 MAPK (New England BioLabs, UK) were measured using western blotting and Molecular Imager ChemiDoc XRS+ System (Bio-Rad, UK). The results were calculated as ratios of phosphorylated relA to relA, phosphorylated p44/42 MAPK to p44/42 MAPK and phosphorylated p38 MAPK to p38 MAPK, normalized to loading control vinculin (Abcam, UK), and presented as fold changes of density relative to controls. All the antibodies used were diluted according to the manufacturer’s instructions. Methods of qPCR and western blotting were as previously described .
Results are presented as mean ± SEM. For statistical analysis, unpaired Student’s t test was used for individual group comparisons. One-way ANOVA for independent samples was used, followed by Tukey’s test for individual group comparisons. A value of p < 0.05 was regarded as statistically significant. The analysis and presentation were performed using Prism 5 (GraphPad, USA).
IL-6 and IL-1β mediate inflammatory responses in MacCM-stimulated preadipocytes
The plasma level of IL-6 is almost exclusively determined by whole-body adiposity and thus closely associated with metabolic syndrome . Moreover, IL-6 has been found to stimulate the synthesis of C-reactive protein, which is one of the strongest indicators of metabolic risk . Hence, we speculated that IL-6 might mediate inflammatory responses in MacCM-stimulated preadipocytes. To test this, we blocked IL-6 action from MacCM-stimulated preadipocytes using IL-6 antibody. In preliminary work, a range of IL-6 antibody doses were tested based on calculations using the manufacturer’s instructions, and (Additional file 1: Fig. S1PA and S1PB) the results show that 300 ng/ml was the optimal dose to inhibit cytokine secretion and gene expression. In accordance with this, (Fig. 2) the ELISA results (normalized) show that the secretion of IL-8 was considerably decreased by IL-6 antibody, which was 0.6-fold lower compared with MacCM-stimulated preadipocytes. Likewise, the levels of MCP-1 and RANTES were moderately decreased by 0.3- and 0.2-fold, respectively. Although the concentrations of IL-1β were numerically lower, this did not reach statistical significance. The secretion of IL-6 (and IL-1β later) is not presented, since additional IL-6 (IL-1β) antibodies in the supernatant will affect the accuracy of the ELISA results. Moreover, blocking IL-6 action exerted potent inhibitory effects on cytokine gene expression, (Fig. 3) as the mRNA levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES were all significantly lowered by 0.4- to 0.7-fold. Therefore, IL-6 propagates and maintains inflammatory responses during adipose tissue metaflammation, since blocking IL-6 action inhibits the secretion and gene expression of IL-1β, IL-6, IL-8, MCP-1 and RANTES in MacCM-stimulated preadipocytes.
A recent study from our group demonstrated that IL-1β could target preadipocytes to induce adipose tissue metaflammation . Likewise, the current results show that IL-1β is crucial in mediating inflammatory responses in macrophage-stimulated preadipocytes, (Fig. 2) since by blocking IL-1β action from MacCM-stimulated preadipocytes with IL-1β antibody (15 μg/ml), the secretion levels of IL-6 and IL-8 were moderately reduced by 0.5-fold compared with MacCM-stimulated preadipocytes. However, the release of MCP-1 and RANTES were not statistically different in the presence of MacCM compared with the control. In parallel, (Fig. 3) blocking IL-1β action markedly decreased the mRNA levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES by 0.4- to 0.7-fold in MacCM-stimulated preadipocytes.
IL-6 and IL-1β increase the phosphorylation of inflammatory signaling molecules in MacCM-stimulated preadipocytes
A possible mechanism for induction of adipose tissue metaflammation is activation of the NF-κB signaling pathway via phosphorylation of transcription factor relA . In our study, (Fig. 6b) MacCM considerably increased the phosphorylation levels of relA by 180%, (Fig. 6a) though the levels of NF-κB were similar compared with the control. In accordance with that, the NF-κB signaling pathway could be activated by IL-1β , (Fig. 6b) since the decreased phosphorylation levels of relA were significantly associated with blocking IL-1β action.
The conventional MAPKs including p44/42 and p38, are activated through phosphorylation, and are established as playing an important role in various biological processes, especially inflammation . Firstly, (Fig. 6a and Additional file 2: Fig. S2A) compared to the control, MacCM had no effect on the levels of p44/42 MAPK and p38 MAPK. Secondly, (Fig. 6c) the phosphorylation of p44/42 MAPK were moderately increased by 60% in MacCM-stimulated preadipocytes. In parallel, (Additional file 2: Fig. S2B) MacCM remarkably increased the phosphorylation of p38 MAPK, which was 250% higher than observed in the control. Furthermore, it is interesting to note that IL-6 triggers inflammatory responses by activating the p44/42 MAPK signaling pathway , as indicated by our observation that the phosphorylation levels of p44/42 MAPK were significantly decreased by blocking IL-6 action in MacCM-stimulated preadipocytes (Fig. 6c).
In addition, (Fig. 6c and Additional file 2: Fig. S2B) show that after antibody blockade of IL-1β, the phosphorylation of p44/42 MAPK and p38 MAPK were slightly lower in MacCM-stimulated preadipocytes, but the difference from control was not statistically significant. Likewise, (Fig. 6b and Additional file 2: Fig. S2B) blocking IL-6 action did not affect the phosphorylation levels of relA or p38 MAPK.
1α,25(OH)2D3 inhibits pro-inflammatory secretion and gene expression in MacCM-stimulated preadipocytes
Therefore, 1α,25(OH)2D3 attenuates IL-1β and IL-6-mediated inflammatory responses in MacCM-stimulated preadipocytes. In addition, (Figs. 2, 3) 10 nM of 1α,25(OH)2D3 generally reduced pro-inflammatory secretion and gene expression, (Figs. 4, 5) but there was no consistent dose–response relationship between the pro-inflammatory secretion or gene expression and the doses of 1α,25(OH)2D3 used in our study.
1α,25(OH)2D3 decreases the phosphorylation of relA of the NF-κB signaling pathway and p44/42 MAPK in MacCM-stimulated preadipocytes
Overall, 1α,25(OH)2D3 decreases the phosphorylation of inflammatory signaling molecules including relA and p44/42 MAPK in MacCM-stimulated preadipocytes, but only 10 nM of 1α,25(OH)2D3 exerted such effects in MacCM-stimulated preadipocytes.
The initial results show that in human white preadipocytes, MacCM massively enhanced the secretion and gene expression of major pro-inflammatory factors including IL-1β, IL-6, IL-8, MCP-1 and RANTES, which have been measured as indicators of adipose tissue metaflammation in keeping with published studies [14, 24, 28, 29, 30, 31]. Although downstream markers of adipose tissue inflammation such as leptin and adiponectin are of interest , these adipokines are usually secreted by mature adipocytes; preadipocytes express and secrete extremely low levels of adiponectin and leptin, which we did test in this study (data not shown). Interestingly, we also found that TNF-α, one of the major pro-inflammatory factors released from adipocytes in metaflammation , was not secreted at detectable levels from MacCM-stimulated preadipocytes. Hence, it appears that preadipocytes have a unique secretome compared to mature adipocytes during metaflammation.
Considered as an adipokine , IL-6 is also a multifaceted, pleiotropic cytokine and suggested to play a central role in the development of metabolic syndrome by inducing metaflammation and insulin resistance . Hence, rather than neutralizing IL-1β in MacCM as formally established , we blocked IL-6 and IL-1β action during the stimulation, to determine whether either of them could mediate the inflammatory responses in MacCM-stimulated preadipocytes. The present study showed that both IL-6 and IL-1β mediate MacCM-stimulated inflammatory responses in preadipocytes by increasing the phosphorylation of relA of the NF-κB pathway and p44/42 MAPK, respectively. Moreover, it might be suggested that IL-6 exerts broader inflammatory effects on preadipocytes, for most of the pro-inflammatory factors (though not IL-1β) were inhibited when IL-6 action was blocked, whilst the chemoattractants MCP-1 and RANTES were not significantly reduced by IL-1β blockade. However, it is clear that IL-1β is also important as its blockade did significantly attenuate the inflammatory responses.
A body of evidence has revealed that metaflammation might be a critical link between metabolic syndrome and cardiovascular disease . Our results suggest that vitamin D might be an independent protective factor to cardiovascular risk due to its anti-inflammatory properties, and given that it also influences several phases of the atherosclerotic process, especially influencing vascular remodeling and atherothrombosis . Moreover, given the benefits of canakinumab seen in the CANTOS trial , along with the present findings, IL-1β blocker and 1α,25(OH)2D3 might complete each other to attenuate metaflammation in adipose tissue, thus to potentially help prevent metabolic syndrome and subsequent cardiovascular disease.
1α,25(OH)2D3 attenuates IL-6 and IL-1β-mediated inflammatory responses, probably by inhibiting p44/42 and relA phosphorylation in MacCM-stimulated human white preadipocytes.
CB and JZ conceived the study. JZ performed the experiments and analyzed the results. JW and CB supervised the findings of this study. JW and JZ discussed the results and contributed to the final manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its additional information files].
Consent for publication
Ethics approval and consent to participate
This work was supported by the China Scholarship Council, with a grant awarded to Jingjing Zhu (No. 201306920002).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 16.Lira FS, Rosa JC, Cunha CA, Ribeiro EB, do Nascimento CO, Oyama LM, et al. Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation. Lipids Health Dis. 2011;10:37.CrossRefGoogle Scholar
- 19.Feroze-Merzoug F, Berquin IM, Dey J, Chen YQ. Peptidylprolyl isomerase A (PPIA) as a preferred internal control over GAPDH and beta-actin in quantitative RNA analyses. BioTech. 2002;32(4):776–8, 80, 82.Google Scholar
- 25.Zhu J, Bing C, Wilding JPH. Vitamin D receptor ligands attenuate the inflammatory profile of IL-1beta-stimulated human white preadipocytes via modulating the NF-kappaB and unfolded protein response pathways. Biochem Biophys Res Commun. 2018. https://doi.org/10.1016/j.bbrc.2018.06.115.CrossRefPubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.